CN1230442C - 5位和6位修饰的促性腺素释放激素拮抗剂 - Google Patents

5位和6位修饰的促性腺素释放激素拮抗剂 Download PDF

Info

Publication number
CN1230442C
CN1230442C CNB988060337A CN98806033A CN1230442C CN 1230442 C CN1230442 C CN 1230442C CN B988060337 A CNB988060337 A CN B988060337A CN 98806033 A CN98806033 A CN 98806033A CN 1230442 C CN1230442 C CN 1230442C
Authority
CN
China
Prior art keywords
xaa
4aph
ala
hor
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988060337A
Other languages
English (en)
Chinese (zh)
Other versions
CN1259959A (zh
Inventor
G·森普尔
姜广成
J·E·F·里维耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1230442(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Publication of CN1259959A publication Critical patent/CN1259959A/zh
Application granted granted Critical
Publication of CN1230442C publication Critical patent/CN1230442C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB988060337A 1997-04-11 1998-04-13 5位和6位修饰的促性腺素释放激素拮抗剂 Expired - Lifetime CN1230442C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,042 1997-04-11
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists

Publications (2)

Publication Number Publication Date
CN1259959A CN1259959A (zh) 2000-07-12
CN1230442C true CN1230442C (zh) 2005-12-07

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988060337A Expired - Lifetime CN1230442C (zh) 1997-04-11 1998-04-13 5位和6位修饰的促性腺素释放激素拮抗剂

Country Status (36)

Country Link
US (2) US5925730A (enExample)
EP (1) EP1003774B1 (enExample)
JP (2) JP4249806B2 (enExample)
KR (1) KR100519421B1 (enExample)
CN (1) CN1230442C (enExample)
AR (1) AR011217A1 (enExample)
AT (1) ATE319736T1 (enExample)
AU (1) AU728642B2 (enExample)
BR (1) BR9808523B1 (enExample)
CA (1) CA2286190C (enExample)
CY (2) CY1108063T1 (enExample)
CZ (1) CZ299097B6 (enExample)
DE (2) DE122009000033I2 (enExample)
DK (1) DK1003774T3 (enExample)
EE (1) EE03974B1 (enExample)
ES (1) ES2260833T3 (enExample)
FR (1) FR09C0028I2 (enExample)
HR (1) HRP980197B1 (enExample)
HU (1) HU224836B1 (enExample)
IL (1) IL132303A0 (enExample)
LU (1) LU91585I2 (enExample)
MY (1) MY114811A (enExample)
NL (1) NL300395I2 (enExample)
NO (2) NO324991B1 (enExample)
NZ (1) NZ500142A (enExample)
PL (1) PL194509B1 (enExample)
PT (1) PT1003774E (enExample)
RU (1) RU2199549C2 (enExample)
SI (1) SI1003774T1 (enExample)
SK (1) SK285381B6 (enExample)
TR (1) TR199902956T2 (enExample)
TW (1) TW505658B (enExample)
UA (1) UA58547C2 (enExample)
UY (1) UY24958A1 (enExample)
WO (1) WO1998046634A1 (enExample)
ZA (1) ZA983062B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5977302A (en) * 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
EP1689419A4 (en) 2003-11-10 2009-01-14 Reprise Biopharmaceutics Llc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW DOSAGE DESMOPRESSIN
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
ES2538828T3 (es) * 2009-04-24 2015-06-24 Polypeptide Laboratories A/S Método para la fabricación de degarelix
US8722088B2 (en) * 2009-05-01 2014-05-13 Ferring International Center S.A. Pharmaceutical compositions and methods for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
WO2012055903A1 (en) 2010-10-27 2012-05-03 Ferring B.V. Process for the manufacture of degarelix and its intermediates
US9035022B2 (en) 2010-12-22 2015-05-19 Salk Institute For Biological Studies Cyclic CRF antagonist peptides
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
EP2854831B1 (en) 2012-06-01 2024-07-10 Ferring B.V. Manufacture of degarelix
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
ES2885869T3 (es) 2015-12-17 2021-12-15 Fresenius Kabi Ipsum S R L Procedimiento para la fabricación de degarelix y sus productos intermedios
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
CN111943960B (zh) 2019-07-29 2022-02-15 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法
CN118159541A (zh) 2021-11-01 2024-06-07 山东绿叶制药有限公司 促性腺素释放激素拮抗剂及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
ATE144538T1 (de) * 1991-04-25 1996-11-15 Romano Deghenghi Lhrh-antagonisten
EP0683792B1 (en) * 1992-12-18 2001-09-26 Abbott Laboratories Lhrh antagonists having modified aminoacyl residues at postions 5 and 6
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
RU2084458C1 (ru) * 1993-05-27 1997-07-20 Институт высокомолекулярных соединений РАН Декапептид, обладающий противоопухолевой активностью
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂

Also Published As

Publication number Publication date
AU728642B2 (en) 2001-01-11
ATE319736T1 (de) 2006-03-15
KR100519421B1 (ko) 2005-10-06
DE122009000033I2 (de) 2011-07-21
JP4249806B2 (ja) 2009-04-08
NL300395I1 (nl) 2009-09-01
NO2009016I1 (no) 2009-08-10
CY2009008I2 (el) 2012-01-25
NL300395I2 (nl) 2010-01-04
JP3645255B1 (ja) 2005-05-11
SK139699A3 (en) 2000-11-07
BR9808523B1 (pt) 2010-02-09
HRP980197A2 (en) 1999-02-28
CZ358699A3 (cs) 2000-06-14
WO1998046634A1 (en) 1998-10-22
DE122009000033I1 (de) 2009-09-17
KR20010006233A (ko) 2001-01-26
TW505658B (en) 2002-10-11
TR199902956T2 (xx) 2000-08-21
JP2001523229A (ja) 2001-11-20
HK1025104A1 (en) 2000-11-03
NO994906D0 (no) 1999-10-08
CA2286190A1 (en) 1998-10-22
JP2005120101A (ja) 2005-05-12
DE69833751T2 (de) 2006-11-09
MY114811A (en) 2003-01-31
PL194509B1 (pl) 2007-06-29
HRP980197B1 (en) 2002-08-31
HUP0002704A3 (en) 2003-08-28
SI1003774T1 (sl) 2006-08-31
NO2009016I2 (no) 2014-08-25
FR09C0028I1 (enExample) 2009-09-25
CN1259959A (zh) 2000-07-12
RU2199549C2 (ru) 2003-02-27
ES2260833T3 (es) 2006-11-01
AU6969898A (en) 1998-11-11
US6214798B1 (en) 2001-04-10
NO994906L (no) 1999-12-13
HU224836B1 (en) 2006-03-28
CY2009008I1 (el) 2012-01-25
UY24958A1 (es) 2001-03-16
DE69833751D1 (de) 2006-05-04
HUP0002704A2 (hu) 2000-12-28
IL132303A0 (en) 2001-03-19
US5925730A (en) 1999-07-20
NO324991B1 (no) 2008-01-14
UA58547C2 (uk) 2003-08-15
PT1003774E (pt) 2006-05-31
DK1003774T3 (da) 2006-07-03
EE9900479A (et) 2000-06-15
PL336213A1 (en) 2000-06-05
FR09C0028I2 (fr) 2010-06-11
ZA983062B (en) 1998-10-20
SK285381B6 (sk) 2006-12-07
EP1003774A1 (en) 2000-05-31
EE03974B1 (et) 2003-02-17
EP1003774B1 (en) 2006-03-08
CY1108063T1 (el) 2012-01-25
AR011217A1 (es) 2000-08-02
NZ500142A (en) 2001-10-26
BR9808523A (pt) 2000-05-23
CA2286190C (en) 2007-01-09
CZ299097B6 (cs) 2008-04-23
LU91585I2 (fr) 2009-09-17

Similar Documents

Publication Publication Date Title
CN1230442C (zh) 5位和6位修饰的促性腺素释放激素拮抗剂
JP4191259B2 (ja) ＧｎＲＨ拮抗物質
CN1129606C (zh) 七肽催产素类似物
JPH10500397A (ja) Ｇｎｒｈ拮抗剤
CN1280483A (zh) 聚乙二醇－grf偶联物的位点特异性制备
CN1422278A (zh) kahalalide F及相关化合物
CN1871020A (zh) Gh－rh的拮抗类似物(2003)
CN1051914A (zh) 肽类
CN1054857C (zh) 具有胃肠道运动刺激活性的胃动素样多肽
CN1040330C (zh) Ｎ－端改性的抗血管舒缓肽化合物及其制备方法和组合物
CN1876677A (zh) 新型lhrh拮抗剂,其制备方法和药物用途
HK1094586A (en) Novel lhrh-antagonist, production and use thereof as medicament
HK1025104B (en) Gnrh antagonists being modified in positions 5 and 6
HK1057569A (en) Novel lhrh-antagonists, production and use thereof as medicament

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
CX01 Expiry of patent term

Granted publication date: 20051207

CX01 Expiry of patent term